Scientists have developed a breakthrough method for engineering CAR-NK (natural killer) cells—an advanced, immune-based cancer therapy. This innovation, from MIT and Harvard Medical School, overcomes the critical limitation of cell-based therapies: immune rejection of donor cells.
The key is a single-step genetic construct that modifies donor NK cells to both express the cancer-targeting Chimeric Antigen Receptor (CAR) and silence the genes for HLA class 1 surface proteins using siRNA. By removing these “identity markers,” the engineered CAR-NK cells effectively “hide” from the host’s destructive T cells.
This technology makes “off-the-shelf” mass-produced treatments viable, allowing for immediate administration upon diagnosis, unlike the weeks-long process for personalized cell therapies. Testing in humanized mouse models confirmed that these immune-evasive cells not only survive and persist for weeks but also nearly eliminate cancer, while exhibiting a lower risk of severe side effects like cytokine release syndrome.